Leflunomide Arrow

Leflunomide, the active ingredient in Leflunomide Arrow, is an immunomodulator (DMARD) presented as an oral tablet for oral use. It is indicated for the management of rheumatoid arthritis and psoriatic arthritis in adult patients, reducing disease activity and slowing joint damage.

GNH USA supplies Leflunomide Arrow as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for importers. This enables reliable access to essential therapy across diverse healthcare settings.

Leflunomide is used to modify disease activity in autoimmune joint disorders.

- Rheumatoid arthritis: reduces joint inflammation, pain, and structural damage. - Psoriatic arthritis: alleviates skin and joint symptoms and slows disease progression. - Active disease in adults: helps achieve remission when other DMARDs are insufficient.

Leflunomide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Diarrhea: loose stools or increased frequency. - Nausea: feeling of sickness or upset stomach. - Elevated liver enzymes: mild increase in ALT/AST. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Severe liver injury: hepatitis or hepatic failure. - Hematologic abnormalities: low white blood cells, anemia, or thrombocytopenia. - Pulmonary toxicity: interstitial lung disease or severe pneumonia.

Before prescribing Leflunomide, clinicians should consider several safety measures.

- Pregnancy: contraindicated (Category X); avoid use in women who are pregnant or may become pregnant. - Liver function: monitor baseline and periodic liver enzymes; discontinue if significant elevation occurs. - Infection risk: assess for active infections before initiating therapy. - Blood counts: perform regular CBC monitoring for leukopenia or anemia. - Drug interactions: avoid concurrent use with strong CYP1A2 inhibitors or other immunosuppressants without monitoring. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Leflunomide can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP1A2 inhibitors (e.g., fluvoxamine): may increase leflunomide levels, raising toxicity risk. - Warfarin: concurrent use can enhance anticoagulant effect, requiring close INR monitoring. - Live vaccines: immunosuppression may reduce vaccine efficacy and increase infection risk.

Moderate Interactions (Monitor Closely): - Methotrexate: combined immunosuppression may increase risk of hepatic toxicity. - Azathioprine or mycophenolate: additive bone marrow suppression. - NSAIDs: may increase risk of liver enzyme elevation.